Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat rheumatoid arthritis; RT-116 which is in discovery stage for the treatment of obesity; RT-117 for rare diseases; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The company has a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity; Chugai Pharmaceutical Co., Ltd. to commercialize the Chugai Product combining Chugai's Compound, which is in development for hemophilia, and the RaniPill HC oral delivery device for use in humans; and has a research and development collaboration with PegBio Co., Ltd. to expand obesity pipeline across multiple novel candidates. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.…
Rani Therapeutics Eyes 2027 Obesity Data as Oral Biologics Platform Advances
Rani Therapeutics Holdings (NASDAQ: RANI) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 69 employees.
The shares were at 0.5111 USD on 20 November 2026, down 74.7% over 52 weeks. Its 52-week range is 0.5025 USD to 2.155 USD: the price is 76.3% below the high and 1.7% above the low.
Its market capitalisation is 59.03M USD.
Rani Therapeutics Holdings reports return on equity of -89.9%.
It holds more cash than debt, a net cash position of 42.14M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. The next earnings report is expected on 25 March 2027.